Paper17513820
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Hudis CA and 10 others. J Clin Oncol, 2007. Cited by 745 papers, by iCite.
Cite this record
ConductScience Library. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. Papers, record 17513820. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17513820
- Disease
- breast cancer1,032 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Chemotherapy, Adjuvant | Major topic |
| Clinical Trials as Topic | Major topic |
| Endpoint Determination | Major topic |
| Radiotherapy, Adjuvant | Major topic |
| Carcinoma, Ductal, Breast | |
| Carcinoma, Intraductal, Noninfiltrating | |
| Carcinoma, Lobular | |
| Female | |
| Humans | |
| Neoplasm Invasiveness | |
| Neoplasm Recurrence, Local | |
| Survival Rate |
Source PubMed
Trials4
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03078751 | Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer | Results | ClinicalTrials.gov | |
| NCT03081234 | Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer | Results | ClinicalTrials.gov | |
| NCT06412211 | A Clinical Feasibility Study of a Photoacoustic Finder | Background | ClinicalTrials.gov | |
| NCT07220135 | Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer | Background | ClinicalTrials.gov |
Cited by451
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 745 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42923147 | Practical guidance for collecting reproducible time-to-event endpoints in retrospective observational oncology studies. | Front Epidemiol | 2026 | https://conductscience.org/library/papers/42923147 | PubMed |
| 42636977 | Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial. | Ann Oncol | 2026 | https://conductscience.org/library/papers/42636977 | PubMed |
| 42636438 | Tumour-infiltrating lymphocytes differ across MammaPrint® classifications in breast cancer. | Endocr Relat Cancer | 2026 | https://conductscience.org/library/papers/42636438 | PubMed |
| 42557562 | The tumour microenvironment influences long-term tamoxifen benefit in postmenopausal ER+/HER2- breast cancer patients: a secondary analysis of the randomised Stockholm Tamoxifen (STO-3) trial. | BMC Med | 2026 | https://conductscience.org/library/papers/42557562 | PubMed |
| 42499497 | Rapid relapse in triple-negative breast cancer: clinical patterns, platinum resistance, and implications for clonal evolution. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42499497 | PubMed |
| 42490883 | A study on the prognostic assessment of triple-negative breast cancer using habitat analysis of preoperative DCE-MRI subtraction maps. | Front Oncol | 2026 | https://conductscience.org/library/papers/42490883 | PubMed |
| 42438913 | Prognostic analysis according to adjuvant chemotherapy and anti-HER2 therapy following surgery in T1a/b HER2-positive breast cancer. | Korean J Intern Med | 2026 | https://conductscience.org/library/papers/42438913 | PubMed |
| 42384406 | Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial. | JAMA Surg | 2026 | https://conductscience.org/library/papers/42384406 | PubMed |
| 42214557 | Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial. | Ann Oncol | 2026 | https://conductscience.org/library/papers/42214557 | PubMed |
| 42114027 | Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial. | J Clin Oncol | 2026 | https://conductscience.org/library/papers/42114027 | PubMed |
| 41918082 | Prognostic value of pre-treatment serum CA19-9 and lymphocyte-to-monocyte ratio in HR+/HER2- breast cancer: a retrospective cohort study. | BMC Cancer | 2026 | https://conductscience.org/library/papers/41918082 | PubMed |
| 41832961 | Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer. | JNCI Cancer Spectr | 2026 | https://conductscience.org/library/papers/41832961 | PubMed |
| 41774182 | Identifying hormone receptor-positive breast cancer subtypes with recurrence scores derived from pathological data without Ki-67 indices: a clinicopathological study of breast cancer survival in West Asia. | Virchows Arch | 2026 | https://conductscience.org/library/papers/41774182 | PubMed |
| 41712503 | Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up. | J Natl Cancer Inst | 2026 | https://conductscience.org/library/papers/41712503 | PubMed |
| 41699108 | Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer. | Commun Med (Lond) | 2026 | https://conductscience.org/library/papers/41699108 | PubMed |
| 41652501 | Prognostic value of metastatic lymph-node ratio and log-odds of positive nodes after neoadjuvant chemotherapy in breast cancer. | World J Surg Oncol | 2026 | https://conductscience.org/library/papers/41652501 | PubMed |
| 41593108 | Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial. | NPJ Breast Cancer | 2026 | https://conductscience.org/library/papers/41593108 | PubMed |
| 41462298 | Circulating T-cell receptor repertoire and clinicopathological correlations in breast cancer patients: immune repertoire analysis from the VGH-TAYLOR study. | Breast Cancer Res | 2025 | https://conductscience.org/library/papers/41462298 | PubMed |
| 41318535 | Pregnancy-associated breast cancer: gestational weight gain impact and nomogram validation. | BMC Cancer | 2025 | https://conductscience.org/library/papers/41318535 | PubMed |
| 41313969 | Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX). | ESMO Open | 2025 | https://conductscience.org/library/papers/41313969 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| RIBOCICLIB | CHEMBL3545110 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL3545110 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17513820
GET https://conductscience.org/api/papers/v1/17513820/cited_by?page=2